Optimal scheduling increases therapeutic gain of adriamycin combined with hyperthermia

H. Baba, Y. Maehara, H. Takeuchi, S. Inutsuka, K. Sugimachi

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

To maximize the thermal enhancement of antitumor effect and minimize normal tissue damage, the timing of Adriamycin (ADM) administration in relation to hyperthermia was examined. Tumor growth of a subcutaneously transplanted fibrosarcoma as well as damage in nomral tissues were measured in F344 rats treated with variable schedules of ADM and hyperthermia. Simultaneous application of 5 mg/kg i.v. of ADM with hyperthermia (120 min at 41.5°C) resulted in a synergistic antitumor effect, but there was no thermal enchancement of the antitumor activity when 2.5 mg/kg ADM was given. Thermal enhancement of the antitumor effect induced by 5.0 mg/kg ADM was greater when ADM was given 30 min before or just prior to hyperthermia compared to that given during hyperthermia. ADM given prior to hyperthermia caused less damage to normal tissue than that given during hyperthermia, as evidenced by a prolonged survival and lower incidence of ascites and tendency to bleed. Thus ADM administration 30 min before or just prior to hyperthermia resulted in greater therapeutic gains than ADM given during hyperthermia. In the light of these results, the optimal scheduling of administration of ADM with hyperthermia is important for a therapeutic gain for cancer patients.

Original languageEnglish
Pages (from-to)651-654
Number of pages4
JournalAnticancer Research
Volume13
Issue number3
Publication statusPublished - Jan 1 1993

Fingerprint

Doxorubicin
Fever
Therapeutics
Hot Temperature
Fibrosarcoma
Inbred F344 Rats
Ascites
Neoplasms
Appointments and Schedules
Survival
Incidence
Growth

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Baba, H., Maehara, Y., Takeuchi, H., Inutsuka, S., & Sugimachi, K. (1993). Optimal scheduling increases therapeutic gain of adriamycin combined with hyperthermia. Anticancer Research, 13(3), 651-654.

Optimal scheduling increases therapeutic gain of adriamycin combined with hyperthermia. / Baba, H.; Maehara, Y.; Takeuchi, H.; Inutsuka, S.; Sugimachi, K.

In: Anticancer Research, Vol. 13, No. 3, 01.01.1993, p. 651-654.

Research output: Contribution to journalArticle

Baba, H, Maehara, Y, Takeuchi, H, Inutsuka, S & Sugimachi, K 1993, 'Optimal scheduling increases therapeutic gain of adriamycin combined with hyperthermia', Anticancer Research, vol. 13, no. 3, pp. 651-654.
Baba H, Maehara Y, Takeuchi H, Inutsuka S, Sugimachi K. Optimal scheduling increases therapeutic gain of adriamycin combined with hyperthermia. Anticancer Research. 1993 Jan 1;13(3):651-654.
Baba, H. ; Maehara, Y. ; Takeuchi, H. ; Inutsuka, S. ; Sugimachi, K. / Optimal scheduling increases therapeutic gain of adriamycin combined with hyperthermia. In: Anticancer Research. 1993 ; Vol. 13, No. 3. pp. 651-654.
@article{789b886a6d0f4c9da8d829d6642585f5,
title = "Optimal scheduling increases therapeutic gain of adriamycin combined with hyperthermia",
abstract = "To maximize the thermal enhancement of antitumor effect and minimize normal tissue damage, the timing of Adriamycin (ADM) administration in relation to hyperthermia was examined. Tumor growth of a subcutaneously transplanted fibrosarcoma as well as damage in nomral tissues were measured in F344 rats treated with variable schedules of ADM and hyperthermia. Simultaneous application of 5 mg/kg i.v. of ADM with hyperthermia (120 min at 41.5°C) resulted in a synergistic antitumor effect, but there was no thermal enchancement of the antitumor activity when 2.5 mg/kg ADM was given. Thermal enhancement of the antitumor effect induced by 5.0 mg/kg ADM was greater when ADM was given 30 min before or just prior to hyperthermia compared to that given during hyperthermia. ADM given prior to hyperthermia caused less damage to normal tissue than that given during hyperthermia, as evidenced by a prolonged survival and lower incidence of ascites and tendency to bleed. Thus ADM administration 30 min before or just prior to hyperthermia resulted in greater therapeutic gains than ADM given during hyperthermia. In the light of these results, the optimal scheduling of administration of ADM with hyperthermia is important for a therapeutic gain for cancer patients.",
author = "H. Baba and Y. Maehara and H. Takeuchi and S. Inutsuka and K. Sugimachi",
year = "1993",
month = "1",
day = "1",
language = "English",
volume = "13",
pages = "651--654",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "3",

}

TY - JOUR

T1 - Optimal scheduling increases therapeutic gain of adriamycin combined with hyperthermia

AU - Baba, H.

AU - Maehara, Y.

AU - Takeuchi, H.

AU - Inutsuka, S.

AU - Sugimachi, K.

PY - 1993/1/1

Y1 - 1993/1/1

N2 - To maximize the thermal enhancement of antitumor effect and minimize normal tissue damage, the timing of Adriamycin (ADM) administration in relation to hyperthermia was examined. Tumor growth of a subcutaneously transplanted fibrosarcoma as well as damage in nomral tissues were measured in F344 rats treated with variable schedules of ADM and hyperthermia. Simultaneous application of 5 mg/kg i.v. of ADM with hyperthermia (120 min at 41.5°C) resulted in a synergistic antitumor effect, but there was no thermal enchancement of the antitumor activity when 2.5 mg/kg ADM was given. Thermal enhancement of the antitumor effect induced by 5.0 mg/kg ADM was greater when ADM was given 30 min before or just prior to hyperthermia compared to that given during hyperthermia. ADM given prior to hyperthermia caused less damage to normal tissue than that given during hyperthermia, as evidenced by a prolonged survival and lower incidence of ascites and tendency to bleed. Thus ADM administration 30 min before or just prior to hyperthermia resulted in greater therapeutic gains than ADM given during hyperthermia. In the light of these results, the optimal scheduling of administration of ADM with hyperthermia is important for a therapeutic gain for cancer patients.

AB - To maximize the thermal enhancement of antitumor effect and minimize normal tissue damage, the timing of Adriamycin (ADM) administration in relation to hyperthermia was examined. Tumor growth of a subcutaneously transplanted fibrosarcoma as well as damage in nomral tissues were measured in F344 rats treated with variable schedules of ADM and hyperthermia. Simultaneous application of 5 mg/kg i.v. of ADM with hyperthermia (120 min at 41.5°C) resulted in a synergistic antitumor effect, but there was no thermal enchancement of the antitumor activity when 2.5 mg/kg ADM was given. Thermal enhancement of the antitumor effect induced by 5.0 mg/kg ADM was greater when ADM was given 30 min before or just prior to hyperthermia compared to that given during hyperthermia. ADM given prior to hyperthermia caused less damage to normal tissue than that given during hyperthermia, as evidenced by a prolonged survival and lower incidence of ascites and tendency to bleed. Thus ADM administration 30 min before or just prior to hyperthermia resulted in greater therapeutic gains than ADM given during hyperthermia. In the light of these results, the optimal scheduling of administration of ADM with hyperthermia is important for a therapeutic gain for cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=0027255204&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027255204&partnerID=8YFLogxK

M3 - Article

C2 - 8317893

AN - SCOPUS:0027255204

VL - 13

SP - 651

EP - 654

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 3

ER -